Reduced levels of alpha-1-antitrypsin in cerebrospinal fluid of amyotrophic lateral sclerosis patients: a novel approach for a potential treatment

Table 1 Quantification of AAT and IL-23 in CSF of ALS patients and controls

Tested parameter	Tested group	Mean ± SEM	Change^a (%)	Median	Change^a (%)
AAT	Control	38.8 ± 6.0 μg/ml		38.0 μg/ml
AAT	Patient	21.4 ± 3.1 μg/ml*	−45	18.0 μg/ml	−53
IL-23	Control	1259 pg/ml		1229 pg/ml
IL-23	Patient	1647 pg/ml**	+30.8	1678 pg/ml	+36

CSF specimens of patients and controls were determined for AAT and IL-23 by ELISA kit and Human Magnetic Luminex screening assay, respectively. Results are expressed as median or mean ± SEM using Student’s t test for calculating the statistical significance of the difference between the two tested groups. N = 15 for both AAT and IL-23 in ALS group while in the controls n = 14 for AAT and n = 13 for IL-23 determinations
*p = 0.014, **p = 0.012
^aExpresses the percent of change (reduction or elevation) taking the control as 100 %

ISSN: 1742-2094